Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. More Details
Flawless balance sheet and fair value.
Share Price & News
How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALXN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ALXN underperformed the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: ALXN underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Alexion Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHas Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
4 weeks ago | Simply Wall StAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Could Be 45% Below Their Intrinsic Value Estimate
1 month ago | Simply Wall StAlexion Pharmaceuticals (NASDAQ:ALXN) Has A Rock Solid Balance Sheet
Is Alexion Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALXN ($119.67) is trading below our estimate of fair value ($235.4)
Significantly Below Fair Value: ALXN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALXN is poor value based on its PE Ratio (31.4x) compared to the US Biotechs industry average (29.1x).
PE vs Market: ALXN is poor value based on its PE Ratio (31.4x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: ALXN is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: ALXN is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.3x).
How is Alexion Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALXN's forecast earnings growth (29.6% per year) is above the savings rate (2.2%).
Earnings vs Market: ALXN's earnings (29.6% per year) are forecast to grow faster than the US market (22% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALXN's revenue (7.8% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: ALXN's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALXN's Return on Equity is forecast to be low in 3 years time (16.3%).
How has Alexion Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALXN has a large one-off loss of $2.2B impacting its June 30 2020 financial results.
Growing Profit Margin: ALXN's current net profit margins (15.3%) are lower than last year (29.7%).
Past Earnings Growth Analysis
Earnings Trend: ALXN's earnings have grown significantly by 42.7% per year over the past 5 years.
Accelerating Growth: ALXN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ALXN had negative earnings growth (-36.6%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: ALXN's Return on Equity (8.1%) is considered low.
How is Alexion Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ALXN's short term assets ($5.4B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: ALXN's short term assets ($5.4B) exceed its long term liabilities ($5.1B).
Debt to Equity History and Analysis
Debt Level: ALXN's debt to equity ratio (24.1%) is considered satisfactory.
Reducing Debt: ALXN's debt to equity ratio has reduced from 41% to 24.1% over the past 5 years.
Debt Coverage: ALXN's debt is well covered by operating cash flow (97.1%).
Interest Coverage: ALXN earns more interest than it pays, so coverage of interest payments is not a concern.
What is Alexion Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALXN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALXN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ludwig Hantson (57 yo)
Dr. Ludwig N. Hantson, Ph.D., has been Chief Executive Officer at Alexion Pharmaceuticals, Inc. since March 27, 2017. Dr. Hantson has been the President of Synovis Life Technologies Inc. since February 14, ...
CEO Compensation Analysis
Compensation vs Market: Ludwig's total compensation ($USD18.95M) is above average for companies of similar size in the US market ($USD11.20M).
Compensation vs Earnings: Ludwig's compensation has been consistent with company performance over the past year.
|CEO & Director||3.58yrs||US$18.95m||0.043% |
|Executive VP & CFO||1yr||US$4.88m||0.0048% |
|Executive VP and Chief Commercial & Global Operations Officer||1yr||US$5.55m||0.010% |
|Executive VP and Head of Research & Development||3.33yrs||US$5.63m||0.0072% |
|Chief Accounting Officer & Senior VP||no data||no data||0.0064% |
|Head of Investor Relations||no data||no data||no data|
|Executive VP & Chief Compliance Officer||3.33yrs||no data||0.0021% |
|Executive VP||2.67yrs||no data||0.0020% |
|Senior Director of Corporate Communications||no data||no data||no data|
|Interim Chief Human Experience Officer||0.17yr||no data||no data|
|Senior Vice President of Global Culture and Corporate Social Responsibility||3yrs||no data||no data|
|Senior VP & Head of EMEAC Region||2.67yrs||no data||no data|
Experienced Management: ALXN's management team is considered experienced (2.7 years average tenure).
|CEO & Director||3.58yrs||US$18.95m||0.043% |
|Independent Director||5.33yrs||US$470.05k||0.060% |
|Independent Director||3.08yrs||US$445.05k||0.0019% |
|Independent Director||2.75yrs||US$445.07k||0.0022% |
|Independent Chairman of the Board||3.42yrs||US$595.05k||0.0039% |
|Independent Director||2.67yrs||US$470.01k||0.0021% |
|Independent Director||10.67yrs||US$445.05k||0.0089% |
|Independent Director||6.5yrs||US$470.05k||0.0030% |
|Independent Director||2.92yrs||US$445.05k||0.0019% |
Experienced Board: ALXN's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alexion Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Alexion Pharmaceuticals, Inc.
- Ticker: ALXN
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$26.654b
- Shares outstanding: 219.17m
- Website: https://www.alexion.com
Number of Employees
- Alexion Pharmaceuticals, Inc.
- 121 Seaport Boulevard
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALXN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 1996|
|AXP||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Feb 1996|
|AXP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 1996|
|0QZM||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 1996|
|ALXN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Feb 1996|
|ALXN||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Feb 1996|
|AXP-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Feb 1996|
|A1LX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 2 COM||BR||BRL||Dec 2019|
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal he ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/24 00:10|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.